DE69905447T2 - Erythromycin-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel - Google Patents

Erythromycin-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Info

Publication number
DE69905447T2
DE69905447T2 DE69905447T DE69905447T DE69905447T2 DE 69905447 T2 DE69905447 T2 DE 69905447T2 DE 69905447 T DE69905447 T DE 69905447T DE 69905447 T DE69905447 T DE 69905447T DE 69905447 T2 DE69905447 T2 DE 69905447T2
Authority
DE
Germany
Prior art keywords
medicines
preparation
erythromycin derivatives
erythromycin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69905447T
Other languages
English (en)
Other versions
DE69905447D1 (de
Inventor
Constantin Agouridas
Alexis Denis
Claude Fromentin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE69905447D1 publication Critical patent/DE69905447D1/de
Application granted granted Critical
Publication of DE69905447T2 publication Critical patent/DE69905447T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69905447T 1998-11-10 1999-11-09 Erythromycin-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel Expired - Lifetime DE69905447T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9814145A FR2785612A1 (fr) 1998-11-10 1998-11-10 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Publications (2)

Publication Number Publication Date
DE69905447D1 DE69905447D1 (de) 2003-03-27
DE69905447T2 true DE69905447T2 (de) 2003-07-24

Family

ID=9532584

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69905447T Expired - Lifetime DE69905447T2 (de) 1998-11-10 1999-11-09 Erythromycin-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Country Status (28)

Country Link
US (2) US6455505B2 (de)
EP (1) EP1016669B1 (de)
JP (1) JP4698783B2 (de)
KR (1) KR100567695B1 (de)
CN (2) CN1240708C (de)
AR (1) AR025814A1 (de)
AT (1) ATE232879T1 (de)
AU (1) AU766138B2 (de)
BR (1) BR9915236A (de)
CA (1) CA2350651C (de)
CZ (1) CZ20011622A3 (de)
DE (1) DE69905447T2 (de)
DK (1) DK1016669T3 (de)
EA (1) EA200100533A1 (de)
ES (1) ES2189365T3 (de)
FR (1) FR2785612A1 (de)
HR (1) HRP20010335B1 (de)
HU (1) HUP0104035A3 (de)
IL (2) IL142996A0 (de)
NO (1) NO20012272L (de)
NZ (1) NZ511609A (de)
PL (1) PL348098A1 (de)
PT (1) PT1016669E (de)
SI (1) SI20640A (de)
TR (1) TR200101286T2 (de)
TW (1) TWI237027B (de)
WO (1) WO2000027857A2 (de)
ZA (1) ZA200103801B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012675A3 (cs) 1999-01-27 2002-04-17 Pfizer Products Inc. Ketolidová antibiotika
WO2000071557A1 (en) 1999-05-24 2000-11-30 Pfizer Products Inc. 13-methyl-erythromycin derivatives
ATE271062T1 (de) 2000-06-30 2004-07-15 Pfizer Prod Inc Makrolid-antibiotika
JP2004017020A (ja) * 2002-06-20 2004-01-22 Sony Corp コーティング方法および被コーティング粒子
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
EP1794171A2 (de) * 2004-07-28 2007-06-13 Ranbaxy Laboratories, Ltd. Ketolidderivate als antibakterielle wirkstoffe
WO2006046112A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
AU2008316830B2 (en) * 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
DK2358379T3 (en) * 2008-10-24 2016-03-07 Cempra Pharmaceuticals Inc BIOFORSVAR USING TRIAZOLHOLDIGE macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
AU2010292010B2 (en) 2009-09-10 2016-01-07 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
CA2793884C (en) 2010-03-22 2019-09-10 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor
DK2571506T3 (en) 2010-05-20 2017-08-28 Cempra Pharmaceuticals Inc PROCEDURES FOR THE MANUFACTURE OF MACROLIDES AND KETOLIDES AND INTERMEDIATES
EP2613630A4 (de) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc Wasserstoffbindung zur formung von fluorketoliden zur behandlung von krankheiten
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
CA3130061C (en) * 2013-04-04 2024-05-28 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
CA2963815A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
CA2980315A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
EP3190122A1 (de) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. Neuartiger syntheseweg zu solithromycin und reinigung davon
CN106432383A (zh) * 2016-09-14 2017-02-22 重庆两江药物研发中心有限公司 索利霉素及其中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
FR2669337B1 (fr) * 1990-11-21 1995-03-24 Roussel Uclaf Nouveaux derives descladinosyles de l'erythromycine, leur procede de preparation et leur application comme medicaments.
FR2697524B1 (fr) * 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) * 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2719587B1 (fr) * 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2727969B1 (fr) * 1994-12-09 1997-01-17 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2742757B1 (fr) * 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
ATE296832T1 (de) * 1996-09-04 2005-06-15 Abbott Lab 6-o-substituierte ketoliden mit antibakteriellen wirkung
AU4472897A (en) * 1997-03-10 1998-09-29 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives

Also Published As

Publication number Publication date
DE69905447D1 (de) 2003-03-27
HUP0104035A3 (en) 2003-12-29
BR9915236A (pt) 2002-01-08
WO2000027857A3 (fr) 2000-08-17
EP1016669A1 (de) 2000-07-05
TWI237027B (en) 2005-08-01
AU766138B2 (en) 2003-10-09
ATE232879T1 (de) 2003-03-15
HUP0104035A2 (hu) 2002-02-28
NO20012272L (no) 2001-07-10
NZ511609A (en) 2003-07-25
FR2785612A1 (fr) 2000-05-12
JP4698783B2 (ja) 2011-06-08
EP1016669B1 (de) 2003-02-19
IL142996A (en) 2006-12-10
TR200101286T2 (tr) 2001-09-21
ZA200103801B (en) 2002-05-10
US6455505B2 (en) 2002-09-24
CA2350651C (fr) 2010-07-20
IL142996A0 (en) 2002-04-21
AR025814A1 (es) 2002-12-18
CZ20011622A3 (cs) 2001-09-12
US20020028781A1 (en) 2002-03-07
AU1052600A (en) 2000-05-29
KR20010080970A (ko) 2001-08-25
JP2000143689A (ja) 2000-05-26
US6407257B1 (en) 2002-06-18
PL348098A1 (en) 2002-05-06
EA200100533A1 (ru) 2001-10-22
WO2000027857A2 (fr) 2000-05-18
ES2189365T3 (es) 2003-07-01
CN100351238C (zh) 2007-11-28
DK1016669T3 (da) 2003-05-26
HRP20010335B1 (en) 2003-08-31
HRP20010335A2 (en) 2002-06-30
CN1814592A (zh) 2006-08-09
NO20012272D0 (no) 2001-05-09
CA2350651A1 (fr) 2000-05-18
SI20640A (sl) 2002-02-28
CN1240708C (zh) 2006-02-08
PT1016669E (pt) 2003-07-31
KR100567695B1 (ko) 2006-04-05
CN1333782A (zh) 2002-01-30
US20020013281A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
DE69905447D1 (de) Erythromycin-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE69529934T2 (de) Erythromycin-Derivate, Verfahren zur Herstellung und ihre Verwendung als Arzneimittel
DE50114874D1 (de) Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE59908522D1 (de) Benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE69820552D1 (de) 4,4-Dihydroxypyrazolin-5-on-Derivate, Verfahren zu deren Herstellung und Verwendung als Kosmetika
DE69505296T2 (de) Erythromycinderivate, ihre Verfahren zur Herstellung und ihre Verwendung als Arzneimittel
DE69925145D1 (de) 2-aminothiazolederivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DE60033028D1 (de) 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung
DE59909418D1 (de) Arylsubstituierte propanolaminderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE50207522D1 (de) Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
ATE342899T1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE338039T1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE265424T1 (de) Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE222236T1 (de) Neue guanidinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69909209D1 (de) Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung
DE69934781D1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
DE60020010D1 (de) Polymethinverbindungen, Verfahren zu deren Herstellung und deren Verwendung
DE59909606D1 (de) Substituierte 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE69520870D1 (de) Esculetin Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellung
DE60006201D1 (de) 4-Oxatricyclo(4.3.1.1-3,8)undecan-5-on-Derivate und Verfahren zu ihrer Herstellung
DE69423424D1 (de) Esculetinderivate, Verfahren zu deren Herstellung und deren Verwendung als pharmazeutische Zusammensetzungen
DE69716284D1 (de) Erythromycin-derivate, verfahren zur herstellung und verwendung als arzneimittel
ATE209212T1 (de) Aromatische ribose-substituierte derivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel
ATE217008T1 (de) Erythromycinderivate, verfahren zu ihrer herstellung, und ihrer verwendung als arzneimitteln
DE60100690D1 (de) Benzothiadiazinderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC